Related Experiment Video
Updated: Apr 20, 2026

Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
Published on: March 23, 2011
Regulation of synaptic plasticity and cognition by SUMO in normal physiology and Alzheimer's disease
Linda Lee1, Elena Dale2, Agnes Staniszewski2
11] Taub Institute and Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA [2] Department of Neurobiology and Behavior, Columbia University, New York, NY 10032, USA.
Abstract:
Learning and memory and the underlying cellular correlate, long-term synaptic plasticity, involve regulation by posttranslational modifications (PTMs). Here we demonstrate that conjugation with the small ubiquitin-like modifier (SUMO) is a novel PTM required for normal synaptic and cognitive functioning. Acute inhibition of SUMOylation impairs long-term potentiation (LTP) and hippocampal-dependent learning. Since Alzheimer's disease (AD) prominently features both synaptic and PTM dysregulation, we investigated SUMOylation under pathology induced by amyloid-β (Aβ), a primary neurotoxic molecule implicated in AD. We observed that SUMOylation is dysregulated in both human AD brain tissue and the Tg2576 transgenic AD mouse model. While neuronal activation normally induced upregulation of SUMOylation, this effect was impaired by Aβ42 oligomers. However, supplementing SUMOylation via transduction of its conjugating enzyme, Ubc9, rescued Aβ-induced deficits in LTP and hippocampal-dependent learning and memory. Our data establish SUMO as a novel regulator of LTP and hippocampal-dependent cognition and additionally implicate SUMOylation impairments in AD pathogenesis.
Related Concept Videos
Long-term Depression
Calcium Ion Concentration Mechanism
If over...
Long-term Depression
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Alzheimer Disease ll: Pathophysiology
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

